330 related articles for article (PubMed ID: 29343814)
21. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
22. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
23. Metalloestrogenic effects of cadmium are absent in long-term estrogen-deprived MCF-7 cells: Evidence for the involvement of constitutively activated estrogen receptor α and very low expression of G protein-coupled estrogen receptor 1.
Hirao-Suzuki M; Takeda S; Kodama Y; Takiguchi M; Toda A; Ohara M
Toxicol Lett; 2020 Feb; 319():22-30. PubMed ID: 31689473
[TBL] [Abstract][Full Text] [Related]
24. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
25. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
26. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
27. Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer.
Du T; Sikora MJ; Levine KM; Tasdemir N; Riggins RB; Wendell SG; Van Houten B; Oesterreich S
Breast Cancer Res; 2018 Sep; 20(1):106. PubMed ID: 30180878
[TBL] [Abstract][Full Text] [Related]
28. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Marshall C; Dowsett M
J Biol Chem; 2003 Aug; 278(33):30458-68. PubMed ID: 12775708
[TBL] [Abstract][Full Text] [Related]
29. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
[TBL] [Abstract][Full Text] [Related]
30. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
31. CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.
Mitra P; Yang RM; Sutton J; Ramsay RG; Gonda TJ
Oncotarget; 2016 Feb; 7(8):9069-83. PubMed ID: 26812885
[TBL] [Abstract][Full Text] [Related]
32. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.
Hiraki M; Suzuki Y; Alam M; Hinohara K; Hasegawa M; Jin C; Kharbanda S; Kufe D
Sci Rep; 2016 May; 6():26643. PubMed ID: 27217294
[TBL] [Abstract][Full Text] [Related]
33. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
35. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
Jokinen E; Koivunen JP
Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
[TBL] [Abstract][Full Text] [Related]
36. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
Thaler S; Schmidt M; Schad A; Sleeman JP
Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
[TBL] [Abstract][Full Text] [Related]
37. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.
Lee EF; Harris TJ; Tran S; Evangelista M; Arulananda S; John T; Ramnac C; Hobbs C; Zhu H; Gunasingh G; Segal D; Behren A; Cebon J; Dobrovic A; Mariadason JM; Strasser A; Rohrbeck L; Haass NK; Herold MJ; Fairlie WD
Cell Death Dis; 2019 Apr; 10(5):342. PubMed ID: 31019203
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.
Yue W; Fan P; Wang J; Li Y; Santen RJ
J Steroid Biochem Mol Biol; 2007; 106(1-5):102-10. PubMed ID: 17616457
[TBL] [Abstract][Full Text] [Related]
39. BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer.
Shahbandi A; Rao SG; Anderson AY; Frey WD; Olayiwola JO; Ungerleider NA; Jackson JG
Cell Death Differ; 2020 Nov; 27(11):3097-3116. PubMed ID: 32457483
[TBL] [Abstract][Full Text] [Related]
40. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]